Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 329

The DOI matches its Crossref record.

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Vogel, Victor G., Costantino, Joseph P., Wickerham, D Lawrence, Cronin, Walter M., Cecchini, Reena S., Atkins, James N., Bevers, Therese B., Fehrenbacher, Louis, Pajon, Eduardo R., Wade, James L., Robidoux, Andr??, Margolese, Richard G., James, Joan, Lippman, Scott M., Runowicz, Carolyn D., Ganz, Patricia A., Reis, Steven E., McCaskill-Stevens, Worta, Ford, Leslie C., Jordan, V Craig, Wolmark, Norman · 2006 · Obstetrical & Gynecological Survey

Abstract

The selective estrogen receptor modulator (SERM) tamoxifen has long been used to treat both early and advanced breast cancer. Raloxifene is a second-generation SERM that, in addition to combatting osteoporosis, may also lessen the risk of invasive breast cancer in postmenopausal women. The National Surgical Adjuvant Breast and Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR) is a prospective, randomized, double-blind trial conducted at nearly 200 clinical centers throughout North America. Participating were 19,747 postmenopausal women whose mean age was 58.5 years and whose 5-year breast cancer risk was increased at 4.03%. The minimal 5-year risk for entering the trial was 1.66%. The women received either 20 mg tamoxifen or 60 mg raloxifene daily for 5 years. During a mean follow up of 3.9 years, there were 163 cases of invasive breast cancer in women assigned to receive tamoxifen and 268 in those assigned to raloxifene, for respective incidence rates of 4.3 and 4.4 per 1000 and a risk ratio (RR) of 1.02 (95% confidence interval [CI], 0.82–1.28). Noninvasive breast cancers were less numerous in the tamoxifen group (RR, 1.40; 95% CI, 0.98–2.00), but uterine cancers were more frequent in this group (RR, 0.62; 95% CI, 0.35–1.08). No group differences were documented for invasive cancer at other sites, ischemic heart disease events, or strokes. Thromboembolic events were less frequent in raloxifene-treated women. Women in the 2 treatment groups had similar numbers of osteoporotic fractures. Those taking raloxifene had fewer cataracts and underwent fewer cataract surgeries. There was no difference in total deaths, and causes of death were similarly distributed in the 2 groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ogx.0000238648.23538.42

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 329

Metadata

Authors
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., Robidoux, A., Margolese, R. G., James, J., Lippman, S. M., Runowicz, C. D., Ganz, P. A., Reis, S. E., McCaskill-Stevens, W., Ford, L. C., Jordan, V. C., & Wolmark, N.
Venue
Obstetrical & Gynecological Survey
Published
2006-10
Volume
61
Issue
10
Pages
650
ISSN
0029-7828 (ISSN-L)
OpenAlex
W2144013834
Cited by
329
References
0
FWCI
13.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. https://app.cochat.ai/papers/10.1097/01.ogx.0000238648.23538.42
The paper
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., Robidoux, A., Margolese, R. G., James, J., Lippman, S. M., Runowicz, C. D., Ganz, P. A., Reis, S. E., McCaskill-Stevens, W., Ford, L. C., . . . Wolmark, N. (2006). Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. Obstetrical & Gynecological Survey. https://doi.org/10.1097/01.ogx.0000238648.23538.42

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.